Oxford Biomedica and Santen Pharmaceutical entered into an R&D collaboration and Option & Licence Agreement to research and develop gene therapy products for the treatment of an inherited retinal disease. The collaboration includes a licence to use OXB’s LentiVector® platform and access to its industrial-scale manufacturing capabilities.
The collaboration aims to generate pre-clinical proof of concept to treat an inherited retinal disease with lentiviral vectors developed and manufactured by OXB. Oxford Biomedica is entitled to an undisclosed milestone payment on exercise of the option to the LentiVector® platform in addition to the development milestones and up to a 10% royalty on net sales.
Santen has global commercial rights to the programme, while OXB retains an option to co-fund and participate in development and commercialisation in the US and Europe.
John Dawson, Oxford Biomedica’s CEO, said, “We look forward to working together with Santen in a true partnership that will bring to bear our respective capabilities in gene therapy vectors and inherited retinal diseases to maximise the value of this important R&D programme.”